Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?

Anti‐PD‐1/PD‐L1 agents play a crucial part in the treatment of non‐small cell cancer (NSCLC) demonstrating improved overall response rate (ORR) and overall survival (OS). Recent studies evaluating combination treatment with anti‐PD‐1 and anti‐CTLA‐4 suggests improved outcome but also increased toxic...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Thorac Cancer
Hoofdauteurs: Sternschuss, Michal, Peled, Nir, Allen, Aaron M., Dudnik, Elizabeth, Rotem, Ofer, Kurman, Noga, Gal, Omer, Reches, Hiba, Zer, Alona
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons Australia, Ltd 2020
Onderwerpen:
Brief Reports
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396365/
https://ncbi.nlm.nih.gov/pubmed/32548905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13502
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items